2025 Was A Year of Momentum: Science, People and Partners

In our last email and after months of intensive research, we unveiled a wealth of discoveries, breakthrough findings and powerful new insights. In case you missed it, you can still view all of these posters by clicking the button below.

Our scientists’ work drew strong media interest as we explored the therapeutic potential of Psilocybin to treat migraine, highlighting how rigorous neuroscience can open new avenues for treating complex disorders. The corresponding poster has been released (available by clicking below) now that the press conference has finished.

2025’s breakthroughs, press recognition, and team growth have laid the foundation for an incredibly fruitful future: opening new avenues for research, innovation, and collaboration across every program.

👉 View Discoveries 2025

Transpharmation welcomes new leadership team in 2025

Daniel Hutcheson, our new Chief Scientific Officer (joining forces with our longstanding expert Guy Higgins, who is shifting into a scientific advisor role with us)

Ayden Feeney, our new Head of Site (Canada)

Wendy Sauer, our new Head of Sales and Marketing

along with new experts: Yassine Darkby, Pain expert Jolanta Golec, Industry expert

Strong media interest and engagement at key conferences including SFN and AES, showcasing our breakthrough research in migraine, epilepsy, and psychedelic therapeutics.

Conference Highlights

We published numerous papers this year. Here are our highlights:

1. Gut Microbiota Variation in Aging Dogs with Osteoarthritis

Fatemeh Balouei¹, Christina de Rivera², Andrea Paradis², Bruno Stefanon¹, Stephanie Kelly², Noelle McCarthy², Paolo Mongillo³.

¹ Agrifood, Environmental and Animal Science, University of Udine, Via delle Scienze, 206, 33100 Udine, Italy.
² Transpharmation Canada Ltd., Fergus, ON N1M 2W8, Canada.
³ Department of Comparative Biomedicine and Food Science, University of Padova, Viale dell’Universita’ 16, 35020 Legnaro, Italy

👉 View OA Microbiome Paper

2. Pharmacological characterisation of psilocybin and 5-MeO-DMT discriminative cues in the rat and their translational value for identifying novel psychedelics

Guy A Higgins¹², Cam MacMillan¹, Ines de Lannoy³, Carolyn Tyler³, Malik Slassi³

¹ Transpharmation Inc., Fergus, ON, Canada.
² Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
³ Otsuka America Pharmaceutical, Inc., Princeton, NJ, USA.

👉 View Psychedelics Paper

3. A comparative assessment of the antidepressant efficacy of ketamine, psilocybin, and fluoxetine in a chronic stress model (in progress)

Małgorzata Domżalska, Joanna Kwiatkowska, Iwona Cichoń & Ewa Sokołowska Transpharmation Inc., Poland. 👉 View Antidepressant Paper

Our webinars saw over 500 live attendees this year. If you missed any, you can still view the webinar recordings below.

1. Advancing Epilepsy Research: New Strategies for Drug-Resistant Epilepsy and Associated Comorbidities

Melissa Barker-Haliski, PhD, Associate Professor, University of Washington, Department of Pharmaceutics Leo Silenieks, Scientific Director, Transpharmation Ltd Neil Upton, PhD, Former Chief Scientific Officer, Transpharmation Ltd 👉 View Epilepsy Webinar

2. Advancing Psychedelic Compounds: From Preclinical Discovery to Translational Insight

Guy Higgins, PhD, Global CSO, Transpharmation Ltd., Adjunct Professor, Department of Pharmacology & Toxicology, University of Toronto Ewa Sokołowska, PhD, Director & Head, Transpharmation Poland Carolyn Tyler, PhD, Senior Director, McQuade Center for Strategic Research and Development, Otsuka Pharmaceutical Companies (U.S.) 👉 View Psychedelics Webinar

3. AI and Machine Learning Uses in Neuroscience Drug Discovery: Hype and Hope

John Huxter, PhD, Associate Director and Global Head of Rodent Electrophysiology and Data Science, Transpharmation Na Helian, PhD, Associate Professor in Research, University of Hertfordshire, Winthrop Gillis, PhD, Scientific consultant, Self-employed

4. Deconstructing OCD Through the Use of Multiple Operant Behavioral Tasks in Rodents

Guy Higgins, PhD, Global CSO, Transpharmation Ltd., Adjunct Professor, Department of Pharmacology & Toxicology, University of Toronto Parisa Moazen, PhD, Scientific Director, Global Scientific Representative of Cognition and Aging, Transpharmation Ltd. Trevor Robbins, PhD, Professor, Cognitive Neuroscience, University of Cambridge 👉 View OCD Webinar